{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:19:31Z","timestamp":1793823571839,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"CorEvitas LLC"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40744-023-00594-6","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T09:02:02Z","timestamp":1695200522000},"page":"1519-1533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0170-2747","authenticated-orcid":false,"given":"Leslie R.","family":"Harrold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Zueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Benjamin","family":"Nowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Blachley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Lakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Stradford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Venkatachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Tundia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"594_CR38","unstructured":"Harrold L, Zueger P, Nowell WB, Blachley T, Lakin P, Curtis D, et al. Early real-world effectiveness of upadacitinib in rheumatoid arthritis using patient-reported outcomes collected via mobile application [abstract]. Arthritis Rheumatol. 2022;74(suppl 9):2656\u201358."},{"key":"594_CR1","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","volume":"389","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389:2338\u201348.","journal-title":"Lancet"},{"key":"594_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","volume":"33","author":"JR Curtis","year":"2011","unstructured":"Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33:679\u2013707.","journal-title":"Clin Ther"},{"key":"594_CR3","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cells9040880","volume":"9","author":"YJ Lin","year":"2020","unstructured":"Lin YJ, Anzaghe M, Schulke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9:880.","journal-title":"Cells"},{"key":"594_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","volume":"13","author":"JR Kalden","year":"2017","unstructured":"Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017;13:707\u201318.","journal-title":"Nat Rev Rheumatol"},{"key":"594_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/tpj.2017.26","volume":"17","author":"S Bek","year":"2017","unstructured":"Bek S, Bojesen AB, Nielsen JV, Sode J, Bank S, Vogel U, et al. Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. Pharmacogen J. 2017;17:403\u201311.","journal-title":"Pharmacogen J"},{"key":"594_CR6","doi-asserted-by":"publisher","first-page":"i17","DOI":"10.1093\/rheumatology\/key225","volume":"58","author":"PC Taylor","year":"2019","unstructured":"Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58:i17-26.","journal-title":"Rheumatology (Oxford)"},{"key":"594_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/1744666X.2022.2064275","volume":"18","author":"AI Venetsanopoulou","year":"2022","unstructured":"Venetsanopoulou AI, Voulgari PV, Drosos AA. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. Expert Rev Clin Immu. 2022;18:485\u201393.","journal-title":"Expert Rev Clin Immu"},{"key":"594_CR8","unstructured":"FDA. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions [Internet]. US Food and Drug Administration. 2021. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed 14 Dec 2022."},{"key":"594_CR9","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, VanDenBosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:2503\u201312.","journal-title":"Lancet"},{"key":"594_CR10","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind randomized controlled trial. Arthritis Rheumatol. 2019;71:1788\u2013800.","journal-title":"Arthritis Rheumatol"},{"key":"594_CR11","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513\u201324.","journal-title":"Lancet"},{"key":"594_CR12","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511\u201321.","journal-title":"N Engl J Med"},{"key":"594_CR13","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303\u201311.","journal-title":"Lancet"},{"key":"594_CR14","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, Friedman A, Mohamed MF, Chen S, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020;72:1607\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"594_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1186\/s12891-022-05520-5","volume":"23","author":"E Mollard","year":"2022","unstructured":"Mollard E, Pedro S, Schumacher R, Michaud K. Smartphone-based behavioral monitoring and patient-reported outcomes in adults with rheumatic and musculoskeletal disease. BMC Musculoskelet Disord. 2022;23:566.","journal-title":"BMC Musculoskelet Disord"},{"key":"594_CR16","doi-asserted-by":"publisher","DOI":"10.2196\/mhealth.9656","volume":"6","author":"M Crouthamel","year":"2018","unstructured":"Crouthamel M, Quattrocchi E, Watts S, Wang S, Berry P, Garcia-Gancedo L, et al. Using a ResearchKit smartphone app to collect rheumatoid arthritis symptoms from real-world participants: feasibility study. JMIR Mhealth Uhealth. 2018;6: e177.","journal-title":"JMIR Mhealth Uhealth"},{"key":"594_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nyas.13117","volume":"1375","author":"B Munos","year":"2016","unstructured":"Munos B, Baker PC, Bot BM, Crouthamel M, Vries G, Ferguson I, et al. Mobile health: the power of wearables, sensors, and apps to transform clinical trials. Ann N Y Acad Sci. 2016;1375:3\u201318.","journal-title":"Ann N Y Acad Sci"},{"key":"594_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/03009742.2021.1907925","volume":"51","author":"L Uhrenholt","year":"2022","unstructured":"Uhrenholt L, Christensen R, Dreyer L, Schlemmer A, Hauge E-M, Krogh N, et al. Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis: a randomized, crossover, agreement study. Scand J Rheumatol. 2022;51:25\u201333.","journal-title":"Scand J Rheumatol"},{"key":"594_CR19","doi-asserted-by":"publisher","DOI":"10.2196\/19260","volume":"8","author":"BF Seppen","year":"2020","unstructured":"Seppen BF, den Boer P, Wiegel J, ter Wee MM, van der Leeden M, de Vries R, et al. Asynchronous mHealth interventions in rheumatoid arthritis: systematic scoping review. JMIR Mhealth Uhealth. 2020;8: e19260.","journal-title":"JMIR Mhealth Uhealth"},{"key":"594_CR20","first-page":"jrheum.201017","volume":"48","author":"M George","year":"2020","unstructured":"George M, Venkatachalam S, Banerjee S, Baker JF, Merkel PA, Gavigan K, et al. Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemic. J Rheumatol. 2020;48:jrheum.201017.","journal-title":"J Rheumatol"},{"key":"594_CR21","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.rdc.2009.10.008","volume":"35","author":"T Pincus","year":"2009","unstructured":"Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin N Am. 2009;35:773\u20138.","journal-title":"Rheum Dis Clin N Am"},{"key":"594_CR22","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s11136-008-9402-x","volume":"17","author":"C Christodoulou","year":"2008","unstructured":"Christodoulou C, Junghaenel DU, DeWalt DA, Rothrock N, Stone AA. Cognitive interviewing in the evaluation of fatigue items: Results from the patient-reported outcomes measurement information system (PROMIS). Qual Life Res. 2008;17:1239\u201346.","journal-title":"Qual Life Res"},{"key":"594_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jclinepi.2015.08.037","volume":"73","author":"D Cella","year":"2016","unstructured":"Cella D, Lai J-S, Jensen SE, Christodoulou C, Junghaenel DU, Reeve BB, et al. PROMIS fatigue item bank had clinical validity across diverse chronic conditions. J Clin Epidemiol. 2016;73:128\u201334.","journal-title":"J Clin Epidemiol"},{"key":"594_CR24","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3899\/jrheum.200692","volume":"48","author":"JM Kremer","year":"2021","unstructured":"Kremer JM, Pappas DA, Kane K, Greenberg J, Harrold LR, Feathers VL, et al. The clinical disease activity index and the Routine Assessment of Patient Index Data 3 for achievement of treatment strategies. J Rheumatol. 2021;48:1776\u201383.","journal-title":"J Rheumatol"},{"key":"594_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3899\/jrheum.180153","volume":"46","author":"MM Ward","year":"2019","unstructured":"Ward MM, Castrejon I, Bergman MJ, Alba MI, Guthrie LC, Pincus T. Minimal clinically important improvement of Routine Assessment of Patient Index Data 3 in rheumatoid arthritis. J Rheumatol. 2019;46:27\u201330.","journal-title":"J Rheumatol"},{"key":"594_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"key":"594_CR27","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/1471-2474-14-286","volume":"14","author":"LD Hughes","year":"2013","unstructured":"Hughes LD, Done J, Young A. A 5 item version of the Compliance Questionnaire for Rheumatology (CQR5) successfully identifies low adherence to DMARDs. BMC Musculoskelet Disord. 2013;14:286.","journal-title":"BMC Musculoskelet Disord"},{"key":"594_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41927-022-00251-5","volume":"6","author":"HA Hamdeh","year":"2022","unstructured":"Hamdeh HA, Al-Jabi SW, Koni A, Zyoud SH. Health-related quality of life and treatment satisfaction in Palestinians with rheumatoid arthritis: a cross-sectional study. BMC Rheumatol. 2022;6:19.","journal-title":"BMC Rheumatol"},{"key":"594_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40744-019-00168-5","volume":"6","author":"C Radawski","year":"2019","unstructured":"Radawski C, Genovese MC, Hauber B, Nowell WB, Hollis K, Gaich CL, et al. Patient perceptions of unmet medical need in rheumatoid arthritis: a cross-sectional survey in the USA. Rheumatol Ther. 2019;6:461\u201371.","journal-title":"Rheumatol Ther"},{"key":"594_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.reuma.2020.11.003","volume":"18","author":"T Barbich","year":"2022","unstructured":"Barbich T, Cerda OL, Schneeberger EE, Citera G. Adherence to treatment with tofacitinib in patients with rheumatoid arthritis in daily clinical practice. Reumatol Cl\u00edn Engl Ed. 2022;18:164\u20138.","journal-title":"Reumatol Cl\u00edn Engl Ed"},{"issue":"suppl 10","key":"594_CR31","first-page":"111","volume":"72","author":"W Nowell","year":"2020","unstructured":"Nowell W, Curtis JR, Zhao H, Xie F, Stradford L, Curtis D, et al. Participant engagement and adherence in an arthritis power real-world study to capture smartwatch and patient-reported outcome data among rheumatoid arthritis patients [abstract]. Arthritis Rheumatol. 2020;72(suppl 10):111.","journal-title":"Arthritis Rheumatol"},{"key":"594_CR32","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1097\/RHU.0000000000001223","volume":"27","author":"WB Nowell","year":"2019","unstructured":"Nowell WB, Curtis D, Curtis JR. Arthritis power reflects optimal characteristics of apps for rheumatoid arthritis. J Clin Rheumatol. 2019;27:e44\u20135.","journal-title":"J Clin Rheumatol"},{"key":"594_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13075-021-02430-0","volume":"23","author":"WB Nowell","year":"2021","unstructured":"Nowell WB, Gavigan K, Kannowski CL, Cai Z, Hunter T, Venkatachalam S, et al. Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower. Arthritis Res Ther. 2021;23:53.","journal-title":"Arthritis Res Ther"},{"key":"594_CR34","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00296-022-05224-y","volume":"43","author":"F Muehlensiepen","year":"2023","unstructured":"Muehlensiepen F, May S, Hadaschik K, Vuillerme N, Heinze M, Grahammer M, et al. Digitally supported shared decision-making and treat-to-target in rheumatology: a qualitative study embedded in a multicenter randomized controlled trial. Rheumatol Int. 2023;43:695\u2013703.","journal-title":"Rheumatol Int"},{"key":"594_CR35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nbt.3826","volume":"35","author":"Y-FY Chan","year":"2017","unstructured":"Chan Y-FY, Wang P, Rogers L, Tignor N, Zweig M, Hershman SG, et al. The Asthma Mobile Health Study, a large-scale clinical observational study using ResearchKit. Nat Biotechnol. 2017;35:354\u201362.","journal-title":"Nat Biotechnol"},{"key":"594_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamacardio.2016.4395","volume":"2","author":"MV McConnell","year":"2017","unstructured":"McConnell MV, Shcherbina A, Pavlovic A, Homburger JR, Goldfeder RL, Waggot D, et al. Feasibility of obtaining measures of lifestyle from a smartphone app: the MyHeart Counts Cardiovascular Health Study. JAMA Cardiol. 2017;2:67\u201376.","journal-title":"JAMA Cardiol"},{"key":"594_CR37","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00296-022-05263-5","volume":"2","author":"BF Seppen","year":"2023","unstructured":"Seppen BF, Wiegel J, Nurmohamed MT, Bos WH, ter Wee MM. Facilitators and barriers to adhere to monitoring disease activity with ePROs: a focus group study in patients with inflammatory arthritis. Rheumatol Int. 2023;2:677\u201385.","journal-title":"Rheumatol Int"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00594-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00594-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00594-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:39:39Z","timestamp":1700152779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00594-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["594"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00594-6","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial arrangements of the authors with companies whose products may be related to the present manuscript are listed, as declared by the authors. Leslie R. Harrold: Employee and shareholder of CorEvitas, consultant to AbbVie, Bristol Myers Squibb, and Roche, speaker\u2019s bureau for Bristol Myers Squibb. Patrick Zueger: Employee of AbbVie and may hold stock or stock options. W. Benjamin Nowell: Employee of Global Healthy Living Foundation, an independent nonprofit research organization, principal investigator for studies with grant support from AbbVie, Amgen, Janssen, and Scipher Medicine. Taylor Blachley: Former employee of CorEvitas; current employee of Syneos Health. Amy Schrader: Employee of CorEvitas. Paul R. Lakin: Employee of CorEvitas. David Curtis: Employee of Global Healthy Living Foundation, an independent nonprofit research organization. Laura Stradford: Employee of Global Healthy Living Foundation, an independent nonprofit research organization. Shilpa Venkatachalam: Employee of Global Healthy Living Foundation, an independent nonprofit research organization. Namita Tundia: Former employee of AbbVie and may hold stock or stock options; current employee of EMD Serono. Pankaj A. Patel: Employee of AbbVie and may hold stock or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The CorEvitas RA Registry is conducted in accordance with the Declaration of Helsinki 1964 and its later amendments. All participating investigators were required to obtain full board approval for conducting research involving human subjects. Sponsor-level and site-level approval for this sub-study was obtained from the New England Independent Review Board (NEIRB; no. 20201379). All patients provided written informed consent and authorization prior to participating in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}